PMID- 34290322
OWN - NLM
STAT- MEDLINE
DCOM- 20211117
LR  - 20211117
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jul 21
TI  - Joint analysis of D-dimer, N-terminal pro b-type natriuretic peptide, and cardiac 
      troponin I on predicting acute pulmonary embolism relapse and mortality.
PG  - 14909
LID - 10.1038/s41598-021-94346-7 [doi]
LID - 14909
AB  - Previous studies on the adverse events of acute pulmonary embolism (APE) were 
      mostly limited to single marker, and short follow-up duration, from 
      hospitalization to up to 30 days. We aimed to predict the long-term prognosis of 
      patients with APE by joint assessment of D-dimer, N-Terminal Pro-Brain 
      Natriuretic Peptide (NT-ProBNP), and troponin I (cTnI). Newly diagnosed patients 
      of APE from January 2011 to December 2015 were recruited from three hospitals. 
      Medical information of the patients was collected retrospectively by reviewing 
      medical records. Adverse events (APE recurrence and all-cause mortality) of all 
      enrolled patients were followed up via telephone. D-dimer > 0.50 mg/L, 
      NT-ProBNP > 500 pg/mL, and cTnI > 0.40 ng/mL were defined as the abnormal. 
      Kaplan-Meier curve was used to compare the cumulative survival rate between 
      patients with different numbers of abnormal markers. Cox proportional hazard 
      regression model was used to further test the association between numbers of 
      abnormal markers and long-term prognosis of patients with APE after adjusting for 
      potential confounding. During follow-up, APE recurrence and all-cause mortality 
      happened in 78 (30.1%) patients. The proportion of APE recurrence and death in 
      one abnormal marker, two abnormal markers, and three abnormal markers groups were 
      7.69%, 28.21%, and 64.10% respectively. Patients with three abnormal markers had 
      the lowest survival rate than those with one or two abnormal markers (Log-rank 
      test, P < 0.001). After adjustment, patients with two or three abnormal markers 
      had a significantly higher risk of the total adverse event compared to those with 
      one abnormal marker. The hazard ratios (95% confidence interval) were 6.27 (3.24, 
      12.12) and 10.7 (4.1, 28.0), respectively. Separate analyses for APE recurrence 
      and all-cause death found similar results. A joint test of abnormal D-dimer, 
      NT-ProBNP, and cTnI in APE patients could better predict the long-term risk of 
      APE recurrence and all-cause mortality.
CI  - (c) 2021. The Author(s).
FAU - Liu, Xiaoyu
AU  - Liu X
AD  - Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 
      57 East Xinhua Rd, Tangshan, Hebei, China.
FAU - Zheng, Liying
AU  - Zheng L
AD  - Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 
      57 East Xinhua Rd, Tangshan, Hebei, China.
FAU - Han, Jing
AU  - Han J
AD  - Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 
      57 East Xinhua Rd, Tangshan, Hebei, China.
FAU - Song, Lu
AU  - Song L
AD  - Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 
      57 East Xinhua Rd, Tangshan, Hebei, China.
FAU - Geng, Hemei
AU  - Geng H
AD  - Hospital Infection Management Division, Kailuan General Hospital, 57 East Xinhua 
      Rd, Tangshan, Hebei, China. 908860297@qq.com.
FAU - Liu, Yunqiu
AU  - Liu Y
AD  - Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, 
      57 East Xinhua Rd, Tangshan, Hebei, China. tshxnk@163.com.
LA  - eng
PT  - Journal Article
DEP - 20210721
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Peptide Fragments)
RN  - 0 (Troponin I)
RN  - 0 (fibrin fragment D)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Biomarkers/analysis/blood
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/*analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Pulmonary Embolism/*diagnosis/*mortality
MH  - Recurrence
MH  - Risk
MH  - Troponin I/*blood
PMC - PMC8295248
COIS- The authors declare no competing interests.
EDAT- 2021/07/23 06:00
MHDA- 2021/11/18 06:00
PMCR- 2021/07/21
CRDT- 2021/07/22 06:12
PHST- 2021/01/31 00:00 [received]
PHST- 2021/06/30 00:00 [accepted]
PHST- 2021/07/22 06:12 [entrez]
PHST- 2021/07/23 06:00 [pubmed]
PHST- 2021/11/18 06:00 [medline]
PHST- 2021/07/21 00:00 [pmc-release]
AID - 10.1038/s41598-021-94346-7 [pii]
AID - 94346 [pii]
AID - 10.1038/s41598-021-94346-7 [doi]
PST - epublish
SO  - Sci Rep. 2021 Jul 21;11(1):14909. doi: 10.1038/s41598-021-94346-7.